Kathleen Gallagher
Corporate Officer/Principal chez AVIDITY BIOSCIENCES, INC.
Postes actifs de Kathleen Gallagher
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Corporate Officer/Principal | - | - |
| Investor Relations Contact | 01/04/2021 | - | |
| Public Communications Contact | 01/04/2021 | - |
Historique de carrière de Kathleen Gallagher
Anciens postes connus de Kathleen Gallagher
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Public Communications Contact | 01/01/2003 | 01/10/2016 |
| AKCEA THERAPEUTICS, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - |
Formation de Kathleen Gallagher
| Boston University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Israël | 2 |
Opérationnelle
| Public Communications Contact | 3 |
| Investor Relations Contact | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Kathleen Gallagher
- Expérience
